TABLE 1.

Characteristics of selected GWASs.

Trials	Cases (N)	Controls (N)	Sample size (N)	Year of publication	No. of SNPs
Lipoprotein metabolism a	14,010	197,259	211,269	2021	16,380,413
Coronary artery disease (van der Harst and Verweij, 2018)	122,733	424,528	547,261	2017	7,934,254
Aortic aneurysm a	2,825	206,541	209,366	2021	16,380,417
Heart failure (Shah et al., 2020)	47,309	930,014	977,323	2020	7,773,021
Atrial fibrillation (Nielsen et al., 2018)	60,620	970,216	1,030,836	2018	33,519,037
Hypertension b	54,358	408,652	463,010	2018	9,851,867
Old myocardial infarction b	3,340	459,670	463,010	2018	9,851,867
Acute myocardial infarction b	2,321	460,689	463,010	2018	9,851,867
Stroke b	7,055	454,825	461,880	2018	9,851,867
Peripheral vascular disease b	1,456	461,554	463,010	2018	9,851,867
Venous thromboembolism b	4,620	356,574	361,194	2018	11,901,177

^a Output from the Finn GWAS.

^b Output from GWAS, pipeline using Phesant derived variables from UKBiobank.

GWAS, genome-wide association studies.